Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.

Autor: Levy ME; Westat, Rockville, Maryland, USA.; Helix, San Mateo, California, USA., Yang DH; Westat, Rockville, Maryland, USA., Dunne MM; Westat, Rockville, Maryland, USA., Miley K; HealthPartners Institute, Minneapolis, Minnesota, USA., Irving SA; Kaiser Permanente Center for Health Research, Portland, Oregon, USA., Grannis SJ; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; School of Medicine, Indiana University, Indianapolis, Indiana, USA., Weber ZA; Westat, Rockville, Maryland, USA., Griggs EP; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Spark TL; Westat, Rockville, Maryland, USA., Bassett E; Westat, Rockville, Maryland, USA., Embi PJ; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Gaglani M; Baylor Scott & White Health, Temple, Texas, USA.; Texas A&M University College of Medicine, Temple, Texas, USA., Natarajan K; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.; New York Presbyterian Hospital, New York, New York, USA., Valvi NR; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA., Ong TC; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Naleway AL; Kaiser Permanente Center for Health Research, Portland, Oregon, USA., Stenehjem E; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA., Klein NP; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA., Link-Gelles R; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., DeSilva MB; HealthPartners Institute, Minneapolis, Minnesota, USA., Kharbanda AB; Children's Minnesota, Minneapolis, Minnesota, USA., Raiyani C; Baylor Scott & White Health, Temple, Texas, USA., Beaton MA; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA., Dixon BE; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA., Rao S; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Dascomb K; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA., Patel P; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Mamawala M; Baylor Scott & White Health, Temple, Texas, USA., Han J; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA., Fadel WF; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA., Barron MA; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Grisel N; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA., Dickerson M; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Liao IC; Baylor Scott & White Health, Temple, Texas, USA., Arndorfer J; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA., Najdowski M; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Murthy K; Baylor Scott & White Health, Temple, Texas, USA., Ray C; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Tenforde MW; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Ball SW; Westat, Rockville, Maryland, USA.
Jazyk: angličtina
Zdroj: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 Mar; Vol. 18 (3), pp. e13269.
DOI: 10.1111/irv.13269
Abstrakt: Background: Although psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID-19 vaccine effectiveness (VE). This study evaluated risk of COVID-19 hospitalization and estimated mRNA VE stratified by psychiatric disorder status.
Methods: In a retrospective cohort analysis of the VISION Network in four US states, the rate of laboratory-confirmed COVID-19-associated hospitalization between December 2021 and August 2022 was compared across psychiatric diagnoses and by monovalent mRNA COVID-19 vaccination status using Cox proportional hazards regression.
Results: Among 2,436,999 adults, 22.1% had ≥1 psychiatric disorder. The incidence of COVID-19-associated hospitalization was higher among patients with any versus no psychiatric disorder (394 vs. 156 per 100,000 person-years, p < 0.001). Any psychiatric disorder (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.18-1.37) and mood (aHR, 1.25; 95% CI, 1.15-1.36), anxiety (aHR, 1.33, 95% CI, 1.22-1.45), and psychotic (aHR, 1.41; 95% CI, 1.14-1.74) disorders were each significant independent predictors of hospitalization. Among patients with any psychiatric disorder, aHRs for the association between vaccination and hospitalization were 0.35 (95% CI, 0.25-0.49) after a recent second dose, 0.08 (95% CI, 0.06-0.11) after a recent third dose, and 0.33 (95% CI, 0.17-0.66) after a recent fourth dose, compared to unvaccinated patients. Corresponding VE estimates were 65%, 92%, and 67%, respectively, and were similar among patients with no psychiatric disorder (68%, 92%, and 79%).
Conclusion: Psychiatric disorders were associated with increased risk of COVID-19-associated hospitalization. However, mRNA vaccination provided similar protection regardless of psychiatric disorder status, highlighting its benefit for individuals with psychiatric disorders.
(© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje